Form 8-K

8-K — Prestige Consumer Healthcare Inc.

Accession: 0001104659-26-074259

Filed: 2026-06-16

Period: 2026-06-12

CIK: 0001295947

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Entry into a Material Definitive Agreement

Item: Completion of Acquisition or Disposition of Assets

Item: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — tm2618021d1_8k.htm (Primary)

EX-99.1 — EXHIBIT 99.1 (tm2618021d1_ex99-1.htm)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K — FORM 8-K

8-K (Primary)

Filename: tm2618021d1_8k.htm · Sequence: 1

false

0001295947

2026-06-12

iso4217:USD

xbrli:shares

iso4217:USD

xbrli:shares

UNITED

STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM

8-K

CURRENT

REPORT

Pursuant

to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report

(Date of earliest event reported): June 12, 2026

PRESTIGE

CONSUMER HEALTHCARE INC.

(Exact Name

of Registrant as Specified in Charter)

Delaware

001-32433

20-1297589

(State or

Other Jurisdiction of

Incorporation)

(Commission

File Number)

(IRS

Employer Identification No.)

660

White Plains Road, Tarrytown, New York 10591

(Address of Principal Executive Offices) (Zip Code)

(914)

524-6800

(Registrant's telephone number, including

area code)

(Former Name or Former Address, if Changed Since Last Report.)

Check the appropriate box below if the Form 8-K

filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see

General Instruction A.2. below):

¨ Written communications pursuant to Rule 425 under the Securities

Act (17 CFR 230.425)

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange

Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨ Pre-commencement communications pursuant

to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title

of each class

Trading

Symbol(s)

Name

of each exchange on which registered

Common stock, par value $0.01 per share

PBH

New York Stock Exchange

Indicate by check mark whether the registrant

is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2

of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging

Growth Company ¨

an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for

complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Item 1.01 Entry into a Material Definitive Agreement.

New Term Loan Facility

On June 12, 2026 (the “Closing

Date”), Prestige Consumer Healthcare Inc. (the “Company”) and its wholly-owned subsidiary, Prestige Brands, Inc. (the

“Borrower”), entered into that certain Term Loan Credit Agreement (the “Term Loan Credit Agreement”) by and among

the Company, the Borrower, certain other subsidiaries of the Company as guarantors, Citibank, N.A. as administrative agent, the lenders

party thereto and Citibank, N.A., Barclays Bank PLC, Morgan Stanley Senior Funding Inc., Goldman Sachs Bank USA and RBC Capital Markets,

as joint lead arrangers and joint bookrunners.

Proceeds of term loans borrowed

under the Term Loan Credit Agreement in the amount of $1.045 billion were used to finance the Transactions (as defined below) that occurred

on the Closing Date, together with fees and expenses incurred in connection with the closing of the Term Loan Credit Agreement and the

Transactions. The Term Loan Credit Agreement also permits, subject to the satisfaction of certain conditions as more specifically set

forth in the Term Loan Credit Agreement, a second draw (on an uncommitted basis) of term loans in an amount not to exceed $95.0 million

that may be used by the Borrower to finance, in part, the previously announced acquisition of LaCorium Health (the “LaCorium

Acquisition”), which is expected to close in the second quarter of fiscal 2027, together with fees and expenses incurred in connection

with the LaCorium Acquisition. The Term Loan Credit Agreement also allows the Company to borrow additional funds under the Term Loan Credit

Agreement on an uncommitted basis, subject to certain limitations and conditions set forth in the Term Loan Credit Agreement.

Term loans borrowed under

the Term Loan Credit Agreement bear interest, at the Borrower’s option, at a rate per annum equal to (i) Term SOFR plus 2.00% or

(ii) an alternate base rate based on the highest of Citibank, N.A.’s prime rate, the overnight Federal Funds Rate plus 0.50% and

Term SOFR plus 1.00%. Term SOFR shall never be less than 0% and such base rate shall never be lower than 1.00%

The Term Loan Credit Agreement

requires the Borrower to make quarterly amortization payments equal to 0.25% of the aggregate principal amount of the term loans made

on the Closing Date, plus the aggregate principal amount of any additional term loans advanced to fund the LaCorium Acquisition. The Borrower

is permitted to prepay all or a portion of the term loans under the Term Loan Credit Agreement at any time, subject to a 1.0% premium

if the Borrower effects a certain repricing transactions (where the primary purpose thereof is to lower the all-in yield of the Term Loan

Credit Agreement) in the first six months after the Closing Date. Borrowings under the Term Loan Credit Agreement are subject to mandatory

prepayments with the net cash proceeds of certain issuances of debt, certain asset sales and other dispositions and certain casualty events,

and, starting with the fiscal year ending March 31, 2028, with a portion of excess cash flow if the Company’s consolidated first

lien net leverage ratio is greater than 2.75 to 1.00. Repayment of borrowings under the Term Loan Credit Agreement will be subject to

acceleration upon the occurrence of certain customary events of default, including payment defaults, covenant defaults, breaches of representations

and warranties, cross-defaults and cross-acceleration to material indebtedness, certain events of bankruptcy, material attachments, material

judgments, actual or asserted failure of material loan or security documents to be in force and effect or create valid liens, change of

control and certain ERISA events.

The Borrower’s obligations

under the Term Loan Credit Agreement are unconditionally guaranteed by the Company and certain of its domestic wholly-owned subsidiaries,

other than the Borrower. Each of these guarantees is joint and several. The Borrower’s obligations

under the Term Loan Credit Agreement, together with the guarantees, are secured by a perfected security interest in substantially all

of the Borrower’s and the guarantors’ assets.

The Term Loan Credit Agreement

contains certain customary affirmative and negative covenants, including limitations on the Company’s ability and the ability of

the Company’s restricted subsidiaries to: create or incur liens, make loans, investments and acquisitions, incur additional indebtedness,

consolidate, merge or sell all or substantially all of its assets, sell, transfer or otherwise dispose of assets, pay dividends or make

other distributions or repurchase or redeem the Company’s capital stock, change the nature of its business, enter into certain transactions

with affiliates, enter into agreements restricting the Borrower’s restricted subsidiaries’ ability to pay dividends, make

certain accounting changes and prepay, redeem or repurchase subordinated indebtedness or make certain modifications thereto.

Amendment to ABL Credit Agreement

Additionally, on the Closing

Date, the Company and the Borrower entered into Amendment No. 10 (the “ABL Amendment”) to the credit agreement governing the

Company’s asset-based revolving line of credit (as amended, the “ABL Credit Agreement”) originally entered into on January

31, 2012, by and among the Company, the Borrower, certain subsidiaries party thereto as guarantors, the lenders party thereto and Citibank,

N.A., as the administrative agent. Among other modifications, the ABL Amendment (i) increased the aggregate commitments under the ABL

Credit Facility to $225 million and (ii) extended the maturity date of the ABL Credit Agreement to the date that is five years from the

Closing Date. In addition, proceeds of borrowings under the ABL Credit Agreement may be used for the LaCorium Acquisition if after giving

effect to such borrowing, excess availability under the ABL Credit Agreement is no less than the greater of (A) $30,625,000 and (B) 17.5%

of the lesser of (i) aggregate commitments under the ABL Credit Agreement and (ii) the borrowing base under the ABL Credit Agreement.

The administrative agents

and certain of the parties to the Term Loan Credit Agreement and the ABL Credit Agreement and certain of their respective affiliates have

performed in the past, and may perform in the future, banking, investment banking or other advisory services for the Company and its affiliates

from time to time for which they have received, or will receive, customary fees and expenses.

The foregoing descriptions

of the Term Loan Credit Agreement, the ABL Amendment and the transactions contemplated thereby do not purport to be complete and are qualified

in their entirety by reference to the Term Loan Credit Agreement and the ABL Amendment, copies of which will be filed as exhibits to the

Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2026.

Item 2.01 Completion of Acquisition or Disposition of Assets.

June 12, 2026, the Borrower and Medtech Products Inc. (“MedTech”), a wholly-owned subsidiary

of the Company, completed the previously announced acquisition of Breathe Right® and certain other brands (the “Breathe

Right Business”) from Foundation Consumer Brands, LLC and certain of its affiliates, pursuant to an

Asset Purchase Agreement, dated as of March 19, 2026 (the “Purchase Agreement”), for a purchase price of $1.045 billion in

cash (the “Transaction”).

The

foregoing description of the Purchase Agreement does not purport to be complete and is qualified in its entirety by reference to the full

text of the Purchase Agreement, a copy of which was filed as Exhibit 2.3 to the Company’s Annual Report on Form 10-K for the year

ended March 31, 2026, and is incorporated herein by reference.

Item 2.03 Creation of a Direct Financial Obligation or an Obligation

under an Off Balance Sheet Arrangement of a Registrant.

The information set forth in Item 1.01 is incorporated

by herein by reference.

Item 8.01 Other Events.

On June 15, 2026, the Company

issued a press release announcing the Company’s entry into the Term Loan Credit Agreement, the ABL Amendment and the completion

of the Transaction. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein

by reference.

Item 9.01 Financial Statements and Exhibits.

(a) Financial statements of businesses or funds acquired.

The required financial statements of the Breathe Right Business are

not included in this Current Report on Form 8-K. These financial statements will be filed through an amendment to this Current Report

on Form 8-K not later than 71 calendar days after the date that this Current Report on Form 8-K was required to be filed.

(b) Pro forma financial information.

The required pro forma financial information of the Company is not

included in this Current Report on Form 8-K. This information will be filed through an amendment to this Current Report on Form 8-K not

later than 71 calendar days after the date that this Current Report on Form 8-K was required to be filed.

(d) Exhibits.

Exhibit

Description

99.1

Press

Release dated June 15, 2026, announcing the Company's entry into the Credit Agreement, the ABL Amendment and the closing of the Transaction.

104

Cover Page Interactive Data File (the cover page XBRL tags are embedded within the Inline XBRL

document).

SIGNATURES

Pursuant to the requirements

of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto

duly authorized.

Dated:

June 16, 2026

PRESTIGE CONSUMER HEALTHCARE INC.

By:

/s/ Christine Sacco

Name: Christine Sacco

Title: Chief Financial Officer & Chief Operating Officer

EX-99.1 — EXHIBIT 99.1

EX-99.1

Filename: tm2618021d1_ex99-1.htm · Sequence: 2

Exhibit 99.1

Prestige Consumer Healthcare Inc Completes Acquisition of Breathe

Right®

TARRYTOWN, N.Y., June 15, 2026 (GLOBE NEWSWIRE) -- Prestige Consumer

Healthcare Inc. (NYSE:PBH) (“Prestige”) today announced that it has closed the previously announced acquisition of the Breathe

Right® brand and certain other brands.

The closing was finalized pursuant to the terms of the asset purchase

agreement, announced on March 20, 2026, under which Prestige agreed to acquire the Breathe Right® brand and certain other

brands from Foundation Consumer Healthcare for $1.045 billion, or approximately $900 million net of anticipated tax benefits valued at

$150 million. Breathe Right®, created in the 1990s, is an iconic #1 brand synonymous with the nasal strip category. It

will become the company’s largest brand and represents expansion into a new category for Prestige.

The Company financed the transaction with a combination of available

cash on hand and a completed financing of a new Term Loan B.

Further details regarding the transaction and benefits of Prestige

are detailed in a presentation dated March 20, 2026 available on the Company’s website at https://ir.prestigebrands.com/.

About Prestige Consumer Healthcare Inc.

Prestige Consumer Healthcare markets,

sells, manufactures and distributes consumer healthcare products to retail outlets throughout the U.S. and Canada, Australia,

and in certain other international markets. The Company’s diverse portfolio of brands include Breathe Right® nasal strips,

Monistat® and Summer’s Eve® women's health products, BC® and Goody's® pain

relievers, Clear Eyes® and TheraTears® eye care products, DenTek® specialty oral care products,

Dramamine® motion sickness treatments, Fleet® enemas and glycerin suppositories, Chloraseptic® and

Luden's® sore throat treatments and drops, Compound W® wart treatments, Little Remedies® pediatric

over-the-counter products, Boudreaux’s Butt Paste® diaper rash ointments, Nix® lice treatment,

Debrox® earwax remover, Gaviscon® antacid in Canada, and Hydralyte® rehydration

products and the Fess® line of nasal and sinus care products in Australia. Visit the Company's website at www.prestigeconsumerhealthcare.com.

Investor Relations Contact

Phil Terpolilli, CFA, 914-524-6819

irinquiries@prestigebrands.com

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 7

v3.26.1

Cover

Jun. 12, 2026

Cover [Abstract]

Document Type

8-K

Amendment Flag

false

Document Period End Date

Jun. 12, 2026

Entity File Number

001-32433

Entity Registrant Name

PRESTIGE

CONSUMER HEALTHCARE INC.

Entity Central Index Key

0001295947

Entity Tax Identification Number

20-1297589

Entity Incorporation, State or Country Code

Entity Address, Address Line One

660

White Plains Road

Entity Address, City or Town

Tarrytown

Entity Address, State or Province

Entity Address, Postal Zip Code

10591

City Area Code

914

Local Phone Number

524-6800

Written Communications

false

Soliciting Material

false

Pre-commencement Tender Offer

false

Pre-commencement Issuer Tender Offer

false

Title of 12(b) Security

Common stock, par value $0.01 per share

Trading Symbol

PBH

Security Exchange Name

NYSE

Entity Emerging Growth Company

false

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Cover page.

+ References

No definition available.

+ Details

Name:

dei_CoverAbstract

Namespace Prefix:

dei_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration